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Aims: To identify factors associated with glucose control, as measured by HbA1c over 4
years, in people with type 2 diabetes starting insulin therapy.
Methods: CREDIT, an observational cohort study, collected data semi-annually over 4 years,
on people with type 2 diabetes starting any insulin, in 311 centres in 12 countries; 2803
people had data on HbA1c during follow-up. Multivariable backward regression analysis
selected characteristics associated with glycaemic control from a limited number of candi-
date variables.
Results: Before starting insulin therapy, HbA1c was 9.3% (78 mmol/mol) and decreased to
7.6% (60 mmol/mol) after 1 year, and changed little after that. Insulin dose increased from
0.21 U/kg to 0.36 U/kg at 1 year, and then by 0.10 U/kg over the next 3 years. Body weight
increased by 2.0 kg in the first year and increased little thereafter. Poorer glycaemic control
over the 4 years was mainly determined by the HbA1c before starting therapy, after
accounting for the other statistically significant associated variables in multivariable anal-
ysis: higher BMI, younger age, longer diabetes duration, more glucose-lowering drugs, using
basal insulin alone, higher insulin dose and female sex. At 4 years, a higher current insulin
dose was the characteristic most strongly associated with a higher concurrent HbA1c.
Conclusions: HbA1c at the start of insulin therapy was the characteristic most predictive of
later HbA1c, after accounting for other variables associated with HbA1c. This may provide
some justification for earlier insulin introduction to improve glucose control to target.
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* Corresponding author. Tel.: +33 1 45 59 51 61; fax: +33 1 47 26 94 54.
E-mail address: beverley.balkau@inserm.fr (B. Balkau).
Contents available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier .com/locate/diabreshttp://dx.doi.org/10.1016/j.diabres.2015.02.034
0168-8227/# 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 8 ( 2 0 1 5 ) 4 3 2 – 4 4 0 4331. Introduction
Blood glucose control is well recognised as a factor associated
with microvascular complications in people with type 2
diabetes, and there is some evidence that it may slow the
progression of cardiovascular diseases [1,2]. People with type 2
diabetes can often maintain adequate glycaemic control with
appropriate lifestyle and oral glucose-lowering agents, but
timely introduction of insulin therapy is indicated when
glycaemic control is no longer maintained [3]. However, there
is often reluctance to start insulin therapy on the part of both
the physician and the individual with type 2 diabetes, because
of the need for injections, fear of hypoglycaemia and weight
gain [4–6].
Clinical trials have provided invaluable information about
glycaemic control following therapy by differing insulin
therapies. However, the people in clinical trials are highly
selected according to the trial protocol, advised by the more
motivated clinicians who agree to participate in trials, while
participants are closely monitored in line with a trial protocol.
There is less published information about the outcomes of
insulin therapy in current clinical practice, and it is often only
very short term [7].
The Cardiovascular Risk Evaluation in people with Type 2
Diabetes on Insulin Therapy (CREDIT) study was designed in
2006 [8] and aimed to evaluate both the relationship between
blood glucose control and cardiovascular events over 4 years
in people starting insulin therapy, and to provide insight into
current, real-world practices in the management of people
with type 2 diabetes using insulin. In this report, we evaluate
the characteristics, both when starting insulin and at 4 years,
that are associated with glycaemic control during the 4 years
of follow-up and at 4 years.
2. Subjects, materials and methods
2.1. Study design and participants
The CREDIT study design and selection of the people with type
2 diabetes have been reported previously [8]. Briefly, people
were recruited in 311 centres in 12 countries in North America,
Europe and Asia (see Supplementary Table S1) for this non-
interventional, observational, 4-year study. After baseline,
data were collected prospectively. The participants were over
40 years of age, newly started on insulin therapies (12
months), and with an HbA1c measurement in the 3 months
before starting insulin. While follow-up was over 4 years, there
was no fixed study schedule, and physicians were asked to
record data at the usual visits to the clinic, every 6 months. The
starting insulin regimen and dose were at the discretion of the
treating physician, as were any changes of therapy.
The study was approved by recruiting centre ethics
committees, and informed written consent was obtained
from each participant. The study was conducted according to
the principles of the Declaration of Helsinki.
The principal outcome measure for this report is the
average 1–4 year HbA1c, the average at years 1, 2, 3 and 4 after
starting insulin; the HbA1c data used for the 1 year time pointwas the blood sample with a date closest to 1 year, within the
time window 9–18 months after inclusion in the study; similar
windows were used for the 2, 3 and 4-year HbA1c values. The
average of the available yearly values was then used.
The secondary outcome measure is the HbA1c at year 4, at
the end of the study, after 4 years of insulin therapy.
The main variables studied at the start of insulin therapy,
as predictors of the two HbA1c outcome measures, were: sex,
age, physical activity (recorded as some physical activity or
none), smoking status (currently smokes or stopped <1 year;
never smoked or stopped 1 year), family history of premature
cardiovascular disease, micro- or macrovascular disease,
other comorbidities, body mass index (BMI), duration of
diabetes, HbA1c (normalised according to local laboratory
values), number of oral glucose-lowering drugs, diagnosis of
high blood pressure, number of blood pressure-lowering
drugs, insulin regimen (basal alone, basal and short acting,
short acting alone, premix insulin alone, other), total dose of
insulin. At the end of 4 years the following additional variables
were included as potential explanatory factors for HbA1c at 4
years: micro- and/or macrovascular disease or other comor-
bidities during follow-up; number of oral glucose-lowering
drugs, insulin regimen and total insulin dose at 4 years;
change in weight over 4 years; and symptomatic hypoglycae-
mia in the 6 months prior to the 4-year evaluation.
2.2. Statistical analyses
SAS statistical programme version 9.2 (Cary, NC, USA) was
used for all analyses.
The characteristics of participants are described by
percentages and by medians (quartile 1, quartile 4), geometric
means and percentiles. Those with and without the two
HbA1c outcome measures were compared by chi-square and
Student t-tests. The percentage (95% confidence interval [CI])
achieving an HbA1c target of 7.0% at each year is shown
graphically.
Both HbA1c outcome measures were loge transformed for
statistical analysis, as they were right-skewed. The functional
form of the continuous predictive variables was determined in
linear models adjusted for region (six regions – Eastern Europe:
Croatia, Ukraine and Russia; Southern Europe: Italy, Portugal,
Spain; France; Northern Europe: United Kingdom, Finland,
Germany; Japan; Canada) and for random centre effects (to
allow for physician characteristics), by comparing the Akaike
Information Criterion for models with the predictive variables
in linear, loge and restricted cubic spline forms; all continuous
variables (excepting change in weight) were loge transformed.
Univariate analyses of variables predicting the two HbA1c
outcome measures used linear models, adjusted for region, as
a fixed factor and recruiting centres as random effects. For the
multivariable models, variables were selected by a backwards
procedure, limited to effects significant at the conventional
0.05 level. For the HbA1c outcome measure at 4 years, an
additional multivariable model included variables already
selected at starting insulin, along with those measured at 4
years listed above, using a similar backwards selection
procedure.
Predictors of the two HbA1c outcome measures above the
7.0% units HbA1c target were studied using univariate and
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backwards variable selection methods, similar to those above.
3. Results
3.1. Baseline characteristics of people followed for
glycaemic control
Of the 3060 people with type 2 diabetes who were started on
insulin therapy and included in the CREDIT study, 2803 had
HbA1c levels recorded at and after entry (principal outcome:
average 1–4 year HbA1c), of whom 2212 had HbA1c at year 4
(secondary outcome) (Supplementary Fig. S1). The people
with the principal HbA1c outcome available had similar
baseline characteristics to those who were not followed,Table 1 – Characteristicsa of the people with type 2 diabetes sta
principal outcome: average 1–4 year HbA1c (n = 2803), and for th
years (n = 2212). The CREDIT study.
Population
outcome
y HbA1
At start of insulin therapy
Men (%) 51 
Age (y) 61 (54
Physically active (%) 48 
Currently smokes or stopped <1 y (%) 18 
Family history of premature CVD (%) 26 
Microvascular disease (%) 60 
Macrovascular disease (%) 35 
Other comorbidities (%) 30 
BMI (kg/m2) 28.7 (
Duration of diabetes (y) 9.0 (
HbA1c (%) 9.2 (
Glucose-lowering drugs (%) 70 
Diagnosed high blood pressure (%) 69 
Blood pressure-lowering drugs (%) 73 
Insulin regimen
Basal only (%) 52 
Basal and short-acting (%) 14 
Short-acting alone (%) 8 
Premix insulin alone (%) 23 
Other (%) 3 
Insulin dose at starting insulin (U/kg) 0.20
At 4 years or during follow-up
Microvascular disease (%) 
Macrovascular disease (%) 
Other comorbidities (%) 
Glucose-lowering drugs (%) 
Insulin regimen
Basal alone (%) 
Basal and short acting (%) 
Short acting alone (%) 
Premix insulin alone (%) 
Other (%) 
No insulin (%) 
Insulin dose (U/kg) 
Symptomatic hypoglycaemiab (%) 
Severe hypoglycaemiab (%) 
Weight change (kg) 
a Data shown are median (quartile 1, quartile 3), or percentage of popul
b Hypoglycaemia is for the 6 months before the 4-year visit.except for small but statistically significant differences: more
physically active, fewer smoked, more micro- or macro-
vascular disease, and more high blood pressure; for the
secondary HbA1c outcome measure, those studied were more
often women, more physically active, fewer smoked, more
family history of premature CVD, more microvascular
disease, fewer comorbidities, and more treated with short-
acting insulin (23% vs. 18%). The people studied were
distributed across 12 countries (Supplementary Table S1),
with Russia and Japan recruiting the largest numbers of
people.
The characteristics of the populations with the principal
and secondary HbA1c outcomes were very similar (Table 1):
men and women were equally represented, and they were
aged 61 years (median), with a BMI of 28.6–28.7 kg/m2. At the
start of insulin therapy, HbA1c was 9.2–9.3% (77–78 mmol/mol),rted on insulin therapy, for the population with data on the
e population with the secondary outcome: HbA1c data at 4
 with principal
: Average 1–4
c (n = 2803)
Population with secondary
outcome: HbA1c at
year 4 (n = 2212)
49
–69) 61 (54–68)
50
16
27
62
34
29
24.9, 21.9) 28.6 (24.9, 32.8)
5.0, 14.3) 8.9 (5.0, 14.0)
8.1, 10.7) 9.3 (8.1, 10.7)
70
69
72
52
15
8
23
3
 (0.13, 0.36) 0.20 (0.13, 0.34)
50
15
16
64
30
32
2
25
5
6
0.50 (0.32, 0.69)
17
2
2.0 (1.0, 7.0)
ation.
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52% were started on basal insulin alone, 23% with premix
alone, while the median starting insulin dose was 0.20 U/kg;
70% were additionally treated with oral glucose-lowering
drugs when starting insulin therapy.
3.2. Characteristics over the 4 years after starting insulin
therapy
The principal HbA1c outcome measure had a skewed
distribution, with a geometric mean of 7.6% (60 mmol/mol),
an upper quartile of 8.2% (66 mmol/mol), and 4.4% of people
had an HbA1c >10.0% (86 mmol/mol) (Supplementary Fig. S2).
After 1 year, HbA1c was 7.6% (60 mmol/mol) and was fairly
constant thereafter, being 7.5% (58 mmol/mol) at year 4 [9].
While 94% of people had an HbA1c 7.0% (53 mmol/mol)
when starting insulin, this was 67% at year 1 and 65% at year 4
(Supplemental Fig. S3).
The insulin dose increased from 0.21 U/kg (geometric
mean) at starting insulin to 0.36, 0.40, 0.43, and 0.46 U/kg at
years 1–4, respectively [9]. For 46% of people, the insulin
regimen changed over the 4-year time period. At 4 years, fewer
people were treated with basal insulin alone (30% vs. 52% at
baseline), while more were treated with basal plus mealtime
insulin (32% vs. 14%), fewer with short-acting alone (2% vs.
8%), similar percentages with premix insulin (25% vs. 23%) and
with other insulins (5% vs. 3%) (Table 1); 6% were no longer
treated with insulin. Glucose-lowering drugs were recorded in
70% of people at starting insulin and in 64% at 4 years. Body
weight increased over the first year of insulin therapy [9], but
little over the three subsequent years; the median (quartiles) of
weight change over 4 years was 2.0 kg (1.0, 7.0), highly
variable.
3.3. Characteristics associated with the average 1–4 year
HbA1c, the principal outcome measure
The baseline characteristics associated with a higher HbA1c
outcome (Tables 2 and 3) were: absence of other comorbidities
(other than micro- or macrovascular complications, neither of
which showed an association), more glucose-lowering drugs, a
younger age, a higher BMI and a higher baseline HbA1c (all
P < 0.0001); other variables associated with a higher HbA1c
outcome were female sex, a family history of premature CVD,
the insulin regimen (in particular basal insulin alone and
premix insulin alone) and a longer duration of diabetes (all
P < 0.01).
The multivariable analysis predicting higher average 1–4-
year HbA1c, after a backwards selection of baseline char-
acteristics, included eight predictors (Table 4): baseline HbA1c
was by far the strongest predictor, followed by BMI, age and
diabetes duration (all P < 0.0001); other predictors were a
higher number of glucose-lowering drugs, insulin regimen
(specifically basal insulin alone and short-acting alone), and a
higher insulin dose. Similar characteristics were also predic-
tive of an average 1–4-year HbA1c of 7.0% units in a
multivariable analysis (Table 4). However, the starting insulin
dose was only predictive of the continuous HbA1c variable,
while men were more likely than women to achieve the HbA1c
target.3.4. Characteristics associated with HbA1c at year 4, the
secondary outcome measure
The baseline characteristics associated with a higher HbA1c at
year 4 (Tables 2 and 3) were: younger age, higher BMI and
higher baseline HbA1c (all P < 0.0001); fewer non-vascular
comorbidities and more glucose-lowering drugs (both
P < 0.005). Year 4 characteristics associated with a higher
HbA1c were a higher insulin dose, a greater increase in weight,
the insulin regimen (in particular basal and short-acting
insulin) (all P < 0.0001); microvascular disease and fewer
comorbidities during the follow-up, more glucose-lowering
drugs, and lack of hypoglycaemia (all P < 0.02).
After backwards selection of variables, and accounting for
all other variables included as predictors in the multivariable
analysis, baseline HbA1c was again the strongest predictor of
HbA1c at year 4, followed by age (both P < 0.0001), then BMI
diabetes duration and other glucose-lowering drugs, in order
of significance (Table 5). Considering also possible explana-
tory variables at year 4, a higher insulin dose at year 4 was the
most significant predictor, with a higher baseline HbA1c, a
greater number of glucose-lowering drugs at year 4, less
hypoglycaemia in the 6 months before the year 4 visit, as well
as younger age, and a higher BMI at baseline. Furthermore,
the 4-year increase in weight was associated with a higher
HbA1c at year 4, but the effect was minimal after adjusting for
the other variables shown in Table 5: a 5-kg increase in weight
over the 4 years was associated with a 0.01% unit increase in
HbA1c. Characteristics associated with being above the 7.0%
unit target for HbA1c were similar to those above: a higher
baseline HbA1c, being younger, a longer duration of diabetes
and more glucose-lowering drugs. The 4-year data were more
explanatory (Supplementary Table S2): significant factors at 4
years were a higher insulin dose, more glucose-lowering
drugs with an increase in weight, no microvascular disease
during the 4 years of follow-up, as well at baseline, a higher
HbA1c and a longer duration of diabetes. Of note, for
the analyses to target, baseline BMI was not retained in the
multivariable models, but weight change was still statisti-
cally significant.
4. Discussion
In this study of people with type 2 diabetes starting insulin
therapy in routine clinical practice, there was a marked
improvement in glycaemic control at 1 year, which remained
stable over the remaining 3 years of the study. However, at 4
years after starting insulin therapy, only 35% of the partici-
pants had an HbA1c below the general glycaemic target of 7.0%
(53 mmol/mol), with 13% having an HbA1c 9.0% (75 mmol/
mol). The main baseline characteristics associated with poorer
glycaemic control over the 4 years were higher values of
baseline HbA1c, age, BMI, duration of diabetes, number of
other glucose-lowering drugs, insulin regimen (specifically
basal or premix insulins vs. multiple injection regimens), and
finally a higher insulin dose and female sex. For glycaemic
control at the end of the 4 years, a higher concomitant insulin
dose was the most predictive factor, with more glucose-
lowering drugs, weight gain, lack of hypoglycaemia and new
Table 2 – Geometric means (95% CI)a of the principal outcome: average 1–4 year HbA1c, and the secondary outcome: HbA1c
at year 4, according to categorical characteristics at baseline and at 4 years or during follow-up, by univariate regression
analysis (adjusted for region and centre). The CREDIT study.
Average 1–4 years HbA1c (n = 2803) HbA1c at year 4 (n = 2212)
Geometric mean (95% CI) Overall P Geometric mean (95% CI) Overall P
At start of insulin therapy
Sex
Men 7.5 (7.4, 7.6) 0.003 7.5 (7.4, 7.7) 0.5
Women 7.6 (7.5, 7.8) 7.5 (7.4, 7.7)
Physically active
No 7.6 (7.5, 7.7) 0.2 7.5 (7.4, 7.7) 0.8
Yes 7.5 (7.4, 7.7) 7.5 (7.4, 7.7)
Smoking
Current or stopped <1 year 7.6 (7.4, 7.7) 0.08 7.5 (7.4, 7.7) 0.9
Non-smoker 7.6 (7.5, 7.8) 7.5 (7.4, 7.7)
Family history premature CVD
No 7.5 (7.4, 7.7) 0.009 7.5 (7.4, 7.6) 0.2
Yes 7.7 (7.5, 7.8) 7.6 (7.4, 7.8)
Microvascular disease
No 7.6 (7.4, 7.7) 0.9 7.6 (7.4, 7.7) 0.5
Yes 7.6 (7.4, 7.7) 7.5 (7.4, 7.7)
Macrovascular disease
No 7.6 (7.5, 7.7) 0.2 7.5 (7.4, 7.7) 0.3
Yes 7.5 (7.4, 7.7) 7.5 (7.3, 7.6)
Other comorbidities
No 7.6 (7.5, 7.8) <0.0001 7.6 (7.5, 7.7) 0.0004
Yes 7.4 (7.3, 7.6) 7.4 (7.2, 7.6)
Glucose-lowering drugs
None 7.4 (7.3, 7.6) <0.0001 7.4 (7.3, 7.6) 0.004
One 7.5 (7.4, 7.7) 7.5 (7.3, 7.6)
Two 7.7 (7.5, 7.8) 7.6 (7.5, 7.8)
Three or more 7.7 (7.5, 8.0) 7.7 (7.4, 7.9)
Diagnosed high blood pressure
No 7.6 (7.4, 7.7) 0.5 7.6 (7.4, 7.8) 0.07
Yes 7.6 (7.4, 7.7) 7.5 (7.4, 7.6)
Blood pressure drugs
None 7.6 (7.5, 7.8) 0.4 7.6 (7.4, 7.8) 0.2
One 7.6 (7.4, 7.7) 7.5 (7.4, 7.7)
Two 7.5 (7.4, 7.7) 7.5 (7.3, 7.7)
Three or more 7.5 (7.4, 7.7) 7.4 (7.3, 7.6)
Insulin regimen
Basal alone 7.6 (7.5, 7.8) 0.0008 7.6 (7.4, 7.7) 0.09
Basal and short acting 7.4 (7.3, 7.6) 7.4 (7.3, 7.7)
Short acting alone 7.3 (7.1, 7.5) 7.3 (7.1, 7.5)
Premix insulin alone 7.6 (7.5, 7.8) 7.5 (7.3, 7.7)
Other 7.4 (7.2, 7.7) 7.7 (7.3, 8.0)
At 4 years or during follow-up
Microvascular diseaseb
No 7.4 (7.3, 7.6) 0.02
Yes 7.6 (7.5, 7.7)
Macrovascular diseaseb
No 7.5 (7.4, 7.7) 0.6
Yes 7.6 (7.4, 7.8)
Other comorbiditiesb
No 7.6 (7.4, 7.6) 0.02
Yes 7.4 (7.2, 7.6)
Glucose-lowering drugs
None 7.4 (7.3, 7.6) 0.004
One 7.6 (7.4, 7.7)
Two 7.5 (7.3, 7.7)
Three or more 7.8 (7.6, 8.1)
Insulin regimen
Basal alone 7.4 (7.3, 7.6) <0.0001
Basal and short acting 7.7 (7.6, 7.9)
Short acting alone 7.2 (6.9, 7.6)
Premix insulin alone 7.5 (7.4, 7.7)
Other 7.4 (7.2, 7.7)
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Table 2 (Continued )
Average 1–4 years HbA1c (n = 2803) HbA1c at year 4 (n = 2212)
Geometric mean (95% CI) Overall P Geometric mean (95% CI) Overall P
None 7.2 (7.0, 7.5)
Hypoglycaemiac
No 7.6 (7.4, 7.7) 0.0002
Yes 7.3 (7.1, 7.5)
a Data shown are geometric means (95% confidence intervals) from linear regression models.
b Microvascular, macrovascular diseases and other comorbidities were during the 4-year follow-up.
c Hypoglycaemia is defined as confirmed hypoglycaemia within the 6 months prior to 4-year visit.
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poorer control; baseline HbA1c and age remained predictive.
While at first sight it might seem clinically sensible that in
the years after starting insulin therapy, a higher baseline
HbA1c should be a co-predictor of HbA1c, along with BMI and
the starting insulin dose, these variables were retained in
multivariable analysis, so it cannot simply be that they are co-
associated with later poor control due to investigators starting
insulin later in the more obese, and then at higher doses, in
conjunction with more oral agents. Similarly, it is tempting to
attribute both high baseline HbA1c and duration of diabetes to
a relative deficiency of endogenous insulin secretion; again
these characteristics were both retained on multivariable
analysis, suggesting that there may not be a single underlying
unmeasured explanatory factor for predicting poorer blood
glucose control. The independent association of BMI with later
HbA1c could reflect a reluctance of clinicians to titrate the
insulin dose in the more obese (although a higher concomitant
insulin dose at the end of the study was an independent
explanatory factor), or perhaps it is simply a marker of
difficulty in harnessing self-motivation to improve measures
of health status.
The associations of insulin regimen with glucose control
over the 4 years, but not at the end of the study, need a more
complex explanation. It might be expected that basal insulin
alone and premix insulin would be selected for those with
earlier and easier to treat blood glucose control, and thus that
attained HbA1c might be lower. However, for the CREDIT
study, we have already shown that the HbA1c at start ofTable 3 – Univariate regression coefficients (SE)a,b for continuou
1–4 year HbA1c and the secondary outcome: HbA1c at year 4,
years or during follow-up (adjusted for region and centre). Th
Average 1–4 year HbA1c (n = 
Beta (SE) Beta/SE 
At start of insulin therapy
Age (y) 0.143 (0.016) 9.0 
BMI (kg/m2) 0.114 (0.014) 8.0 
Duration of diabetes (y) 0.007 (0.003) 2.4 
HbA1c (%) 0.193 (0.014) 13.91 
Insulin dose (U/kg) 0.000 (0.005) 0.02 
At 4 years or during follow-up
Insulin dose (U/kg) 
Weight change (kg) 
a Data shown are beta coefficients (standard errors) from linear regressi
b HbA1c and continuous variables all loge transformed, except weight chinsulin therapy was not a factor associated with the choice
between basal insulin and insulin regimens other than premix
[8], and indeed basal insulin was more frequent in those taking
more oral glucose-lowering therapies. It appears that at
baseline, basal insulin is chosen for those who have more
difficulty in managing their diabetes. Accordingly, on multi-
variable analysis, neither initial nor current insulin regimen
was predictive of control at 4 years, but their role may be
played out through the concurrent insulin dose.
Hypoglycaemia might a priori be expected to be a factor
explanatory for HbA1c. Clinicians appear to expect lower
HbA1c to be associated with more hypoglycaemia, contrary to
the findings of the ACCORD study for either intensive or
standard therapy [10]. In the CREDIT study, we have found that
an episode of hypoglycaemia in the last 6 months of follow-up
is associated with lower HbA1c at year 4 on multivariable
analysis, although by a modest average of 0.08% units.
However, hypoglycaemia was not experienced by a majority
of people studied, at least in the 6 months before the year 4
visit, and severe hypoglycaemia was uncommon. This must
limit its ability to modulate insulin dose, insulin regimen, or
patient behaviour.
Other publications have addressed this issue in random-
ised controlled trials of insulin regimens [11–13], in retrospec-
tive studies from electronic prescriber databases [14–16] and in
observational studies with features in common with our own
[7,17,18]. Randomised clinical trials however, are generally
restricted to their planned comparison, and are often of short
duration. The 4-T study did suggest that insulin regimen hads variables associated with the principal outcome: average
 according to continuous characteristics at baseline and 4
e CREDIT study.
2803) HbA1c at year 4 (n = 2212)
P Beta (SE) Beta/SE P
<0.0001 0.137 (0.020) 6.9 <0.0001
<0.0001 0.086 (0.018) 4.7 <0.0001
0.01 0.003 (0.004) 0.8 0.4
<0.0001 0.122 (0.018) 6.9 <0.0001
1 0.002 (0.006) 0.4 0.7
0.074 (0.006) 12.7 <0.0001
0.002 (0.001) 4.0 <0.0001
on models.
ange.
Table 4 – Multivariable linear and logistic regression coefficients (SE)a,b and odds ratios (95% confidence intervals) of
variables at the start of insulin therapy associated with the principal outcome: average 1–4 year HbA1c after backwards
selection of variables. The CREDIT study.
Predicting loge HbA1c Predicting HbA1c 7.0%
Beta (SE) Beta/SE P Odds ratio (95% CI) P
HbA1c (%) 0.187 (0.015) 12.8 <0.0001 8.33 (4.55, 14.29) <0.0001
BMI (kg/m2) 0.098 (0.015) 6.7 <0.0001 2.27 (1.32, 4.00) 0.003
Age (y) 0.110 (0.017) 6.5 <0.0001 0.37 (0.19, 0.69) 0.002
Duration of diabetes (y) 0.016 (0.003) 5.4 <0.0001 1.27 (1.12, 1.41) <0.0001
Glucose-lowering drugs 0.007 0.02
One vs. none 0.008 (0.007) 1.0 0.3 0.84 (0.64, 1.10) 0.2
Two vs. none 0.025 (0.008) 3.0 0.003 1.18 (0.87, 1.61) 0.3
Three or more vs. none 0.032 (0.013) 2.5 0.01 1.43 (0.88, 2.33) 0.2
Insulin regimen 0.001 0.0006
Basal + short-acting vs. basal alone 0.043 (0.011) 3.9 <0.0001 0.55 (0.39, 0.78) 0.0006
Short-acting alone vs. basal alone 0.028 (0.012) 2.3 0.02 0.84 (0.55, 1.28) 0.4
Premix alone vs. basal alone 0.005 (0.008) 0.6 0.6 1.22 (0.90, 1.64) 0.2
Other vs. basal alone 0.026 (0.017) 1.5 0.1 0.81 (0.45, 1.47) 0.5
Insulin dose (U/kg) 0.013 (0.006) 2.2 0.03
Sex (women vs. men) 1.41 (1.15, 1.75) 0.0008
a Data shown are beta coefficients (standard errors) from linear regression models to predict HbA1c and odds ratios (95% confidence intervals)
to predict HbA1c <7%, from logistic regression; both regression analyses adjusted for region and centre.
b HbA1c and continuous variables all loge transformed.
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basal insulin having worse glucose control but a better
hypoglycaemia experience than those on premix or mealtime
insulins alone [11]. Regimens in the 4-T study were intensified
over the next 2 years and the contrast changed so that fewer
people on premix insulin achieved a 6.5% (48 mmol/mol)
HbA1c target than those on either basal or mealtime insulin
regimens, although the median HbA1c levels at year 3 were
very similar: 6.9–7.1% units (42–54 mmol/mol) [12]. Riddle et al.
[13] analysed 12 mostly short-term clinical trials, all usingTable 5 – Multivariable linear regression coefficients (SE)a,b of v
year 4, after backwards selection of variables. The CREDIT stu
Baseline predictors 
Beta (SE) Beta/SE 
At starting insulin therapy
HbA1c (%) 0.115 (0.018) 6.3 
Age (y) 0.105 (0.021) 4.9 
BMI (kg/m2) 0.062 (0.018) 3.4 
Duration of diabetes (y) 0.012 (0.004) 3.3 
Glucose-lowering drugs 
One vs. none 0.002 (0.009) 0.3 
Two vs. none 0.023 (0.009) 2.4 
Three or more vs. none 0.024 (0.015) 1.6 
At 4 years or during follow-up
Insulin dose (U/kg) 
Glucose-lowering drugs 
One vs. none 
Two vs. none 
Three or more vs. none 
Hypoglycaemiac
Weight change (kg) 
a Data shown are beta coefficients (standard errors) from linear regressi
b HbA1c and all continuous variables were loge transformed excepting w
c Hypoglycaemia is occurrence of an event in the last 6 months before tstructured titration of glargine. They found that baseline
factors predictive of HbA1c <7.0% (<53 mmol/mol) were male
sex, white race, shorter duration of diabetes, lower baseline
HbA1c, metformin use, and no sulphonylurea use. For the
studies from electronic prescribers and databases and from
observational studies [7,14–18], baseline factors predictive of
HbA1c <7.0% (<53 mmol/mol) identified in at least one study
were lower HbA1c (noted in almost all studies), shorter
duration of diabetes, being older, male sex, white race, no
oral glucose-lowering drugs before starting insulin, a lowerariables associated with the secondary outcome: HbA1c at
dy.
Baseline predictors and explanatory
variables
P Beta (SE) Beta/SE P
<0.0001 0.074 (0.018) 4.0 <0.0001
<0.0001 0.076 (0.021) 3.6 0.0003
0.0008 0.058 (0.019) 3.0 0.003
0.0009
0.03
0.8
0.02
0.1
0.068 (0.006) 10.9 <0.0001
<0.0001
0.019 (0.008) 2.4 0.02
0.037 (0.010) 3.6 0.0003
0.075 (0.018) 4.3 <0.0001
0.031 (0.009) 3.4 0.0007
0.001 (0.000) 2.1 0.04
on models, after adjusting for region and centre.
eight change.
he 4-year visit.
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other regimens, lower family income, presence of comorbid-
ities (peripheral vascular disease, cancer, obesity, kidney
disease; however, there was no association with other micro-
or macrovascular diseases, or with hypertension), less
hypoglycaemia before the start of insulin, and a lower BMI.
At the end of the observation periods, a lower insulin dose, a
better quality of life, no change in oral therapy, and less
hypoglycaemia were associated with a greater reduction of
HbA1c. The findings from these studies taken together are
consistent with our longer-duration study.
A previous report from the CREDIT study compared insulin
regimens using a propensity score of baseline characteristics
to try to overcome the probable confounding factors in the
allocation of specific insulin regimens [19]. Insulin regimens
were compared in sub-populations matched by propensity
scores. After 1 year of insulin therapy, and adjusting for
baseline HbA1c and random recruitment-centre effects, the
only differences between regimens were that people initially
treated with short-acting insulin alone had a higher 1-year
HbA1c than those treated with premix or basal insulin alone;
note that short-acting insulin alone was used by only 8% of our
study population. From the analyses shown here, after
adjusting for other predictive factors, those treated with basal
insulin had on average a higher HbA1c over years 1–4 than those
treated with either basal plus short-acting or short-acting alone.
In contrast, HbA1c at year 4 was strongly associated with the
insulin regimen at year 4 in univariate analysis; in the
multivariable analysis, insulin regimen was no longer associat-
ed, and any effect of the insulin regimen appears to be played by
other more highly associated variables in the model, including
the insulin dose. A likely explanation for this is the prospective
evolution of insulin regimens, as 30% of people begun on basal
insulin added a mealtime insulin during the study, presumably
to achieve improved control [9].
Our study has its limitations. While the participating
physicians were chosen to represent those prescribing insulin
in a given country [8], not all of the physicians invited actually
participated in the study, and those participating are likely to be
the physicians who are more motivated for treating and
controlling glycaemia in people with type 2 diabetes and with
better organised practice. For the insulin therapy, we have no
information on whether insulin analogue or human insulin was
used, nor details of the types of insulin used. As with all
observational studies, we are limited by missing data from
people who were not able to be followed up for the entire
duration of the study. However, the differences in characteristics
of the population studied and the initial population were minor.
With regard to the strengths of this study, it was
prospective and longitudinal with findings over a 4-year
follow-up–much longer than in many other reports. The
results were generally consistent from year 1. The physicians
were free to choose the insulin regimen and its dose when
initiating insulin therapy; as there were no study recommen-
dations on either, it is expected that physicians would have
followed normal practice, both when starting insulin and with
any changes during follow-up. This differs from the prospec-
tive observational studies discussed above, which were
limited to specific insulin analogues, and of shorter duration
[7,17,18]. Our data are those collected and recorded in routinepractice, while the large number of participants and partici-
pating physicians provide a wide range of clinical practices
from the developed world. Accordingly each of the study
variables would have a wide range, thus enhancing the chance
of showing variables with a statistically significant association
(or not) with glycaemic control. However, the large sample size
may also mean that small effects that are clinically insignifi-
cant, and perhaps clinically undetectable, may be statistically
significant. This is the case for weight gain at the end of the
study, where a 1 kg weight gain was associated with only a
0.003% unit (0.03 mmol/mol) increase in HbA1c that was
statistically significantly in multivariable analysis.
The principal characteristics for glycaemic control after
starting insulin therapy thus appear to be a lower starting HbA1c,
a shorter duration of diabetes, a lower number of oral glucose-
lowering drugs, and a lower insulin dose. Together, these
variables seem to point to an advantage in beginning insulin
earlier. Some studies have addressed this point directly, and
while the advantages of very early use of insulin over oral agents
can be disputed, these studies do not suggest much in the way of
detriment either [20,21]. Using the CORE Diabetes Model, Goodall
et al. [22] using data specific to the UK, suggested that starting
insulin rather than continuing oral agents for a further 8 years
would increase lifespan by 7.5 months on average, as well as
improving quality of life. However, individualised and more
patient-centred approaches have been emphasised in recent
recommendations [3,20,23]. While older patients are usually
considered more fragile, it would appear that they are able to
achieve better glycaemic control than their younger counter-
parts, perhaps suggesting a cautious but optimistic approach to
insulin provided other comorbidities are not present.
In conclusion, the glycaemic control of these people with
type 2 diabetes starting on insulin therapy, improved
markedly by the end of the first year, and this level was
maintained over the three subsequent years. However, the
major determinant of success was a low baseline HbA1c,
supported by lower BMI, higher age, lower starting insulin
dose, and a shorter duration of diabetes. At the 4-year follow-
up the predictive characteristics were similar, but concurrent
low insulin dose was highly predictive, as well as a lower
number of oral glucose-lowering drugs. Given the impact of
HbA1c at starting insulin therapy, and also the duration of
diabetes, it would appear that the timing of starting insulin
therapy may be crucial in the longer-term maintenance of
good glycaemic control.
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